Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplant in HIV-infected patient with acute myeloid leukaemia

Bone Marrow Transplantation volume 53, pages 1518–1521 (2018)Cite this article

Subjects

This article has been updated

Allogeneic stem cell transplantation (Allo-HSCT) is sine qua non to cure high-risk acute myeloid leukaemia (AML). In spite the advent of highly active antiretroviral treatment, HIV-infected patients display a remarkable risk for haematological neoplasms such as non-Hodgkin lymphomas, Hodgkin lymphoma and acute leukaemia. Several case series have confirmed the efficacy of the autologous stem cell transplantation for the treatment of non-Hodgkin lymphomas in the HIV setting. Nonetheless, there is a paucity of data for the role of the Allo-HSCT in HIV-infected individuals with haematological malignancies. Herein, we presented the successful long-term outcome of a HIV-infected patient who received reduced intensity conditioned, matched unrelated donor transplant with alemtuzumab as graft-versus-host disease prophylaxis for therapy-related acute myeloid leukaemia. We propose that Allo-HSCT in HIV patients is safe and that alemtuzumab-based conditioning could further work to eradicate HIV in those whose donor is not CCR5 homozygous.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Change history

  • 05 February 2019

    The original article was updated shortly after publication to correct the word ‘transplantat’ in the title to ‘transplant’.

References

  1. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus–infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101:317–24.

    Article  Google Scholar 

  2. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306–13.

    Article  CAS  Google Scholar 

  3. Kuritzkes DR. Hematopoietic stem cell transplantation for HIV cure. J Clin Invest. 2016;126:432–7.

    Article  Google Scholar 

  4. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human mmunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.

    Article  CAS  Google Scholar 

  5. Dies-Martin J, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al. Comparable survival between HIV+ and HIV − Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma patients undergoing an autologous peripheral blood stem cell transplantation. A retrospective analysis of the EBMT Lymphoma working party. Blood. 2007;110:24.

    Google Scholar 

  6. Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, et al. Allogeneic Hematopoietic Stem Cell Transplantation in HIV positive patients with malignant and non-malignant disorders: a report from the centre for international blood and marrow transplant research (CIBMTR). Biol Blood Marrow Transplant. 2007;13:5–6.

    Article  Google Scholar 

  7. Johnston C, Harrington R, Jain R, Schiffer J, Kiem HP, Woolfrey A. Safety and efficacy of combination antiretroviral therapy in human immunodeficiency virus-infected adults undergoing autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22:149–56.

    Article  CAS  Google Scholar 

  8. Serrano D, Miralles P, Balsalobre P, Kwon M, Rodriguez-Macias G, Gayoso J, et al. Graft-versus-tumour effect after allogeneic stem cell transplantation in HIV-positive patients with high-risk hematologic malignancies. AIDS Res Hum Retrovir. 2013;29:1340–5.

    Article  CAS  Google Scholar 

  9. Hütter G. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med. 2014;371:2437–8.

    Article  Google Scholar 

  10. Koelsch KK, Rasmussen TA, Hey-Nguyen WJ, Pearson C, Xu Y, Bailey M, et al. Impact of allogeneic hematopoietic stem cell transplantation on the HIV reservoir and immune response in 3 HIV-infected individuals. J Acquir Immune Defic Syndr. 2017;75:328–37.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematology and Stem Cell Transplantation Department Heart of England NHS Trust, Birmingham, United Kingdom

    A. Kanellopoulos, M. Kaparou, E. Xenou, S. Paneesha, B. Kishore, R. Lovell, K. Holder, J. Suhr, L. Baker, L. Ryan & E. Nikolousis

Authors
  1. A. Kanellopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kaparou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Xenou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Paneesha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Kishore
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Lovell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Holder
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Suhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. Nikolousis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Nikolousis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanellopoulos, A., Kaparou, M., Xenou, E. et al. Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplant in HIV-infected patient with acute myeloid leukaemia. Bone Marrow Transplant 53, 1518–1521 (2018). https://doi.org/10.1038/s41409-018-0297-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0297-z

This article is cited by

Search

Advanced search

Quick links